Tirzepatide (Mounjaro, Zepbound)
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist. Beyond its original T2DM indication (Mounjaro), the Zepbound formulation gained expanded 2024–2025 approvals for chronic weight management, moderate-to-severe obstructive sleep apnea in adults with obesity, and—per the SUMMIT trial—HFpEF with obesity.
- Mechanism of action
- Selective agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing glucose-dependent insulin release, glucagon suppression, and reduced appetite.
- Administration route
- Subcutaneous injection once weekly
FDA-approved indications (2026)
Type 2 diabetes
Adjunct to diet/exercise to improve glycemic control in adults (Mounjaro).
Chronic weight management
Zepbound for BMI ≥30 or ≥27 with weight-related comorbidity.
Obstructive sleep apnea with obesity
Zepbound approved for moderate-to-severe OSA in adults with obesity (FDA approval Dec 2024; SURMOUNT-OSA).
HFpEF with obesity
SUMMIT (2024) demonstrated reduced HF events and improved KCCQ score; guideline incorporation ongoing in 2026 (flagged: incorporation varies by society).
Dosing: adult, renal, and hepatic
| Population | Dose |
|---|---|
| T2DM / weight management | Start 2.5 mg SC weekly × 4 wk → 5 mg weekly; increase in 2.5 mg increments every ≥4 wk. Max 15 mg weekly. |
| Renal impairment | No dose adjustment. Monitor for volume depletion with GI adverse events. |
| Hepatic impairment | No dose adjustment. Limited data in severe hepatic impairment. |
Contraindications and boxed warnings
Contraindications
- Personal or family history of medullary thyroid carcinoma.
- MEN2 syndrome.
- Prior serious hypersensitivity to tirzepatide.
Boxed warnings
- Risk of thyroid C-cell tumors (rodent data).
2026 guideline and pivotal trial position
ADA 2026 positions tirzepatide alongside semaglutide as a preferred option when substantial A1c and weight reduction are both required, with head-to-head SURPASS-2 data showing superiority over semaglutide 1 mg. For weight management, AACE and The Obesity Society (TOS) 2025 statements elevate tirzepatide to first-line among pharmacotherapies in suitable candidates. The HFpEF indication is emerging in 2026 guidelines after SUMMIT.
SURPASS-2
Superior A1c reduction vs semaglutide 1 mg at 40 weeks; greater weight loss.
SURMOUNT-1
Up to 22.5% mean weight loss at 15 mg over 72 weeks in adults with obesity (no T2DM).
SURMOUNT-OSA (2024)
Substantial reductions in AHI and symptom burden in adults with obesity and moderate-to-severe OSA.
SUMMIT (2024)
Reduced HF events and improved quality of life in HFpEF + obesity.
Cross-system reasoning
Tirzepatide compresses multiple disease domains — glycemia, weight, obstructive sleep apnea, and heart failure with preserved ejection fraction — into one agent. For a patient with T2DM, OSA on CPAP, and suspected HFpEF, tirzepatide reduces the need for poly-specialist layering while demanding coordinated monitoring for GI side effects, gallstone disease, and pancreatitis. Delayed gastric emptying has the same perioperative implications as semaglutide; anesthesiology guidance applies.
Key references
- FDA Label — Mounjaro / Zepbound
- Frías JP, et al. SURPASS-2 (NEJM 2021)PMID: 34170647
- Jastreboff AM, et al. SURMOUNT-1 (NEJM 2022)PMID: 35658024
- Malhotra A, et al. SURMOUNT-OSA (NEJM 2024)PMID: 38912654
Related clinical reading
Explore Tirzepatide in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
This reference is for US-licensed physicians and is not a substitute for the full FDA prescribing information. Dosing in special populations, drug interactions, and emerging safety information should be verified against the current manufacturer label and society guidelines before prescribing.